Targeting DNA methylation for treating triple-negative breast cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Triple-negative breast cancer (TNBC) represents 15-20% of invasive breast cancers, characterized by aggressive histology and poor prognosis.
• Unlike other breast cancer subtypes, TNBC lacks US FDA-approved targeted therapies, necessitating novel treatment strategies.
• Aberrant DNA methylation is a key epigenetic mechanism in cancer, often silencing tumor suppressor genes.

Purpose of the Study:

• To explore the potential of DNA methyltransferase inhibitors as a targeted therapy for triple-negative breast cancer.
• To investigate the reactivation of silenced tumor suppressor genes by DNA methyltransferase inhibitors in the context of TNBC.

Main Methods:

• Review of existing literature on DNA methylation, DNA methyltransferase inhibitors, and their effects in hematologic and solid tumors.
• Analysis of the mechanism of action of DNA methyltransferase inhibitors in reactivating tumor suppressor genes.
• Focus on the application and potential therapeutic benefits of these inhibitors in triple-negative breast cancer.

Main Results:

• DNA methyltransferase inhibitors have demonstrated therapeutic effects in hematologic malignancies by reactivating silenced tumor suppressor genes.
• The antitumor effects of DNA methyltransferase inhibitors are being explored in solid tumors, including TNBC.
• Reactivation of tumor suppressor genes by these inhibitors can lead to tumor growth arrest.

Conclusions:

• DNA methyltransferase inhibitors represent a promising therapeutic strategy for triple-negative breast cancer due to the lack of current targeted treatments.
• Targeting aberrant DNA methylation offers a novel approach to overcome the aggressive nature and poor outcomes associated with TNBC.
• Further research into DNA methyltransferase inhibitors could lead to the development of effective therapies for TNBC patients.